Significance of Bladder Biopsies in Ta,T1 Bladder Tumors: A Report from the EORTC Genito-Urinary Tract Cancer Cooperative Group

Meijden, A. Van Der; Oosterlinck, W; Brausi, Maurizio; Kurth, K. H.; Sylvester, Richard; deBalincourt, Christine; Committee, and Members of the EORTC-GU Group Superficial Bladder

doi:10.1159/000019859

Cited by 153 publications

(85 citation statements)

References 12 publications

(10 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, Witjes and colleagues,194 in a study of 1026 patients, claimed that random biopsies were of little value in determining patients' prognosis. In a study by van der Meijden and colleagues, 216 the authors stated that in approximately 90% of patients the biopsies of normal-appearing urothelium in patients with stage Ta or T1 bladder cancer showed no abnormalities and therefore did not contribute to staging or to the correct choice of adjuvant therapy following TURBT. Jichlinski and colleagues 65 stated that random biopsies of normal urothelium remained a subject of controversy and did not recommend their use in the general population of patients with non-muscle-invasive bladder cancer.…”

Section: Random Biopsiesmentioning

confidence: 99%

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Campbell

Skea²,

Sutherland³

et al. 2010

Health Technol Assess

251

207

View full text Add to dashboard Cite

How to obtain copies of this and other HTA programme reports An electronic version of this title, in Adobe Acrobat format, is available for downloading free of charge for personal use from the HTA website (www.hta.ac.uk). A fully searchable DVD is also available (see below).Printed copies of HTA journal series issues cost £20 each (post and packing free in the UK) to both public and private sector purchasers from our despatch agents.Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per issue and for the rest of the world £3 per issue. How to order:-fax (with credit card details) -post (with credit card details or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you to either print out your order or download a blank order form. Contact details are as follows:Synergie UK (HTA Department) Digital House, The Loddon Centre Wade Road Basingstoke Hants RG24 8QW Email: orders@hta.ac.uk Tel: 0845 812 4000 -ask for 'HTA Payment Services' (out-of-hours answer-phone service) Fax: 0845 812 4001 -put 'HTA Order' on the fax header Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to University of Southampton and drawn on a bank with a UK address. Paying by credit cardYou can order using your credit card by phone, fax or post. SubscriptionsNHS libraries can subscribe free of charge. Public libraries can subscribe at a reduced cost of £100 for each volume (normally comprising 40-50 titles). The commercial subscription rate is £400 per volume (addresses within the UK) and £600 per volume (addresses outside the UK). Please see our website for details. Subscriptions can be purchased only for the current or forthcoming volume. How do I get a copy of HTA on DVD?Please use the form on the HTA website (www.hta.ac.uk/htacd/index.shtml). HTA on DVD is currently free of charge worldwide.The website also provides information about the HTA programme and lists the membership of the various committees. NIHR Health Technology Assessment programmeT he Health Technology Assessment (HTA) programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA programme is needs led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. F...

show abstract

Section: Random Biopsiesmentioning

confidence: 99%

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Campbell

Skea²,

Sutherland³

et al. 2010

Health Technol Assess

251

207

View full text Add to dashboard Cite

show abstract

“…The importance of detecting and locating such highly aggressive tumours is obvious. By contrast with the cited studies on random biopsies [21,22], FC provides high sensitivity for these malignant lesions.…”

Section: Fig 2 Fluorescing Cis When Using Fcmentioning

confidence: 64%

“…Currently the taking of random biopsies is recommended by different guidelines if the cytological findings are positive in combination with negative showed that routine random biopsies will not significantly influence the management of patients [22]. Therefore the benefit of random biopsies should at least be questioned, as the detection rate is low, the urothelium is traumatized and there is a possible risk of tumour-cell seeding [23].…”

Section: Discussionmentioning

confidence: 99%

Positive urine cytology but negative white‐light cystoscopy: an indication for fluorescence cystoscopy?

et al. 2009

View full text Add to dashboard Cite

OBJECTIVETo evaluate the possible benefit of fluorescence cystoscopy (FC) in detecting cytologically ‘confirmed’ lesions when assessing urothelial carcinoma of the bladder, as negative white‐light cystoscopy in cases of a positive cytological finding represents a diagnostic dilemma.PATIENTS AND METHODSFrom January 1996 to December 2006, 348 patients, who had cystoscopy for surveillance or due to suspicion of urothelial carcinoma, presented with an entirely negative white‐light cystoscopy at our hospital. However, 77 of the 348 patients (22.2%) were diagnosed with a positive cytological finding. All patients had white‐light cystoscopy first and a bladder‐wash cytological specimen was obtained, then FC, followed by cold‐cup biopsies and/or transurethral resection of the bladder tumour.RESULTSIn the 77 patients with a positive cytological specimen FC enabled the detection of the precise site of malignancy within the bladder in 63 (82%). As malignant or premalignant lesions, there were 18 moderate dysplasias, 27 carcinoma in situ (CIS), and 18 pTa‐1/G1‐3 tumours. Moreover using FC, malignant or premalignant lesions were detected in 43 of 271 patients (15.9%) who had a negative cytological specimen (15 moderate dysplasias, six CIS, 22 pTa‐1/G1‐3).CONCLUSIONThis study shows that FC is beneficial in the detection of malignant and premalignant lesions, if there is negative white‐light cystoscopy but positive urine cytology. The immediate identification of the exact site of a malignant lesion during FC enables the physician to diagnose and treat these patients more accurately and with no delay.

show abstract

“…Geçmişte KİS'i tespit etmeye yönelik olarak normal görünen mesane mukozasından random biyopsiler alınması gündeme gelmiştir. Ancak yapılan araştırmalarda bu uygulamanın avantajının düşük olduğu ayrıca biyopsi alınmasının mesane içinde mukozal bariyerin bozulduğu alanlara tümör implantasyonu riskini arttırabileceğinden rekürrens açısından potansiyel bir tehlike oluşturabileceği bildirilmektedir (9). Bundan dolayı KİS'in tespit edilmesinde daha ileri tetkiklere gereksinim olduğu açıktır.…”

Section: Introductionunclassified

Kasa İnvaze Olmayan Mesane Kanserinde Hex Aminolevulinat Sistoskopisiyle Fotodinamik Tanı: Meta-Analizler Eşliğinde Değerlendirme

Tüzel¹

2014

uob

View full text Add to dashboard Cite

Fotodinamik tanının (FDT) prensibi tümör hücreleri tarafından yüksek oranda emilen foto-duyarlaştırıcı bir ajanın mesane içine instile edilmesini takiben neoplastik hücrelerin mavi-viyole illüminasyon altında kırmızı floresans yayması sonucu görünürlüklerinin arttırılması temeline dayanmaktadır. Fotodinamik tanı ile hem mesane tümörlerinin görülebilmesinin iyileştirilmesi hem de tümör rezeksiyonlarının daha komplet yapılabilmesinin sağlanması amaçlanmaktadır. Bu şekilde rekürrens oranlarının azalacağı ve hastalıksız sağkalımın artacağı öngörülmektedir. Bu derlemede fotodinamik tanısal sistoskopinin kasa invaze olmayan mesane kanseri (KİOMK) tanısındaki yerinin ve tedavi sonuçları üzerine olan etkisinin konuyla ilgili meta-analizler eşliğinde gözden geçirilmesi amaçlanmıştır. Fotodinamik tanısal sistoskopinin KİOMK tanı ve tedavisindeki yerini araştıran dört adet meta-analiz ve bir adet geniş kapsamlı derleme yayınlanmıştır. Çok sayıda prospektif randomize çalışmada FDT sistoskopinin mesane tümörü tespit edebilmede tek başına beyaz ışık eşliğinde yapılan sistoskopiden üstün olduğu gösterilmiştir. Toplamda ise FDT sistoskopi ile KİS tespit etme oranının yaklaşık olarak %25-%30 oranında daha fazla olduğu bildirilmektedir. Meta-analizlerin tümünde rezidüel tümör oranlarının FDT sistoskopi uygulanan hastalarda istatistiksel olarak anlamlı derecede düşük olduğu bulunmuştur. FDT sistoskopinin temel limitasyonu %1 ile %26 arasında değişen yanlış pozitiflik oranlarıdır. Muhtelif randomize çalışmalarda yan etki yönünden FDT sistokopisi ile beyaz ışık kılavuzluğunda yapılan sistoskopinin yan etkiler açısından farklı olmadığı tespit edilmiştir. KİOMK'inde beyaz ışık eşliğinde yapılan sistoskopiye göre FDT ile öncelikle KİS ve displazi gibi flat lezyonlarda tümör tespitinin daha iyi olduğu ve rezidüel tümör oranının azalıyor olduğu konusunda seviye 1 ve 2 kanıt bulunmaktadır. Bu şekilde hastalığın rekürrens oranlarında anlamlı azalma olduğu çoğu randomize çalışmada teyit edilmiştir. FDT sistoskopi ile hastalığın progresyon oranları azalmamaktadır. (Üroonkoloji Bülteni 2014;13:113-118) Anah tar Ke li me ler: Fotodinamik tanı, kasa invaze olmayan mesane kanseri, hexyl aminolevulinate, 5--Aminolevulinik asit The principle of photodynamic diagnosis (PDD) is based on the interaction between a photosensitizing agent with a high uptake by tumor cells and light with an appropriate wavelength which is absorbed by the agent as high energy per photon and re-emitted with a lower energy per photon, thus, visualization is enhanced under under blue light.PDD offers improved visualization of bladder tumors while allowing a more complete transurethral resection. This may facilitate decreased recurrence rates and improved recurrence-free survival. The aim of this review was to evaluate the role of PDD on the diagnosis and treatment of bladder cancer in the light of current meta-analysis. Recently, 4 metaanalysis and a contemporary review have been published on the topic of PDD. Several prospective randomized studies have shown the superio...

show abstract

Significance of Bladder Biopsies in Ta,T1 Bladder Tumors: A Report from the EORTC Genito-Urinary Tract Cancer Cooperative Group

Cited by 153 publications

References 12 publications

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Systematic review of the clinical effectiveness and cost-effectiveness of photodynamic diagnosis and urine biomarkers (FISH, ImmunoCyt, NMP22) and cytology for the detection and follow-up of bladder cancer

Positive urine cytology but negative white‐light cystoscopy: an indication for fluorescence cystoscopy?

Kasa İnvaze Olmayan Mesane Kanserinde Hex Aminolevulinat Sistoskopisiyle Fotodinamik Tanı: Meta-Analizler Eşliğinde Değerlendirme

Contact Info

Product

Resources

About